Evidence map›Paper›PMID 41604465›Full record

ArticleScience translational medicine2026

A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma.

Zhongqiu Xie, Pawel Ł Janczyk, Robert Cornelison, Sarah Lynch, Martyna Glowczyk-Gluc, Becky Leifer, Yiwei Wang, Philip Hahn, Johnathon D Dooley, Adelaide Fierti and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Inhibiting advillin in glioblastoma.Nature reviews. Drug discovery · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Zhongqiu XieDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0002-2869-7669
Pawel Ł JanczykDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Robert CornelisonDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Sarah LynchDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0001-6173-6511
Martyna Glowczyk-GlucDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0009-0006-2222-0604
Becky LeiferDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0009-0009-7973-5643
Yiwei WangDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0009-0005-5697-2276
Philip HahnDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.ORCID 0000-0003-2864-8063
Johnathon D DooleyDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Adelaide FiertiDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0002-9024-1865
Xinrui ShiDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0009-0003-1739-8895
Yiyu ZhangDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0001-8636-2827
Tingxuan LiDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Qiong WangDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0003-2564-7778
Zhi ZhangDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Laine MarrahDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0003-1745-8539
Angela KoehlerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0001-6980-5534
James W MandellDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Michael HilinskiDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.ORCID 0000-0003-2861-7099
Hui LiDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0002-7879-1792

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
Targeting AVIL in GlioblastomaR01CA240601 · NCI · UNIVERSITY OF VIRGINIA · PI LI, HUI · 2020 to 2024
$2.4M
Targeting AVIL, a novel oncogene in rhabdomyosarcomaR01CA269594 · NCI · UNIVERSITY OF VIRGINIA · PI HUI LI · 2023 to 2026
$2.0M
NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA240601NCI NIH HHS R01 CA269594
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common and deadliest malignancy of the brain. Despite decades of intense research, there has been little change to the overall survival of patients with GBM. Our laboratory recently identified the actin-binding protein advillin (AVIL) as being overexpressed, oncogenic, and necessary for tumorigenesis in GBM. Here, we further examined AVIL expression in GBMs and found that it was enriched across molecular subtypes and states, including GBM stem cells and temozolomide-resistant samples. In contrast, we found that AVIL was scarcely expressed in normal human brain tissue. In addition,

Indexed as

Antineoplastic AgentsBrain NeoplasmsGlioblastomaMicrofilament ProteinsSmall Molecule LibrariesActinsAnimalsCell Line, TumorHumansMiceMice, KnockoutNeoplastic Stem CellsXenograft Model Antitumor AssaysActinsAntineoplastic AgentsMicrofilament ProteinsSmall Molecule Libraries

Identifiers

PMID41604465
PMCPMC13688261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.